EIKON THERAPEUTICS INC (EIKN)
Health Care · Preclinical and clinical-stage biopharmaceuticals · NASDAQ
A preclinical and clinical-stage biotech company advancing a multi-program pipeline leveraging its proprietary drug discovery platform.
What EIKON THERAPEUTICS INC does
Eikon Therapeutics is a preclinical and clinical-stage biopharmaceutical company developing a pipeline of product candidates across multiple therapeutic areas. The company is leveraging its technology platform to advance drug discovery and development, with named programs including EIK1001, EIK1003, EIK1004, EIK1005, EIK1006, and an ARv7 program. The company is advancing these candidates through preclinical studies and clinical trials with plans for regulatory filings and commercialization if approved.
Themes: ["Clinical trial development"]
Fundamentals
- Price$11.22 as of 2026-07-09 close
- Market cap$580M as of 2026-07-10
- 1-year return-28.5% as of 2026-07-09 close
- ROE-114.8% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta2.16 as of 2026-07-10
Key risks (from latest filing)
["Reliance on third parties for clinical trial conduct and manufacturing of product candidates, creating execution and timeline risks"]
Competitors & peers
- Specific direct competitors not clearly identified in provided filing text
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.